AIIMS, ISRO Sign Space Medicine Pact to Boost Human Spaceflight, Healthcare Research

IMT News Desk
IMT News Desk
· 3 min read
AIIMS New Delhi and ISRO’s Human Space Flight Centre have signed an MoU to advance space medicine research, focusing on astronaut health, ageing-like changes in microgravity and translational benefits for patients on Earth.

India’s premier medical institute AIIMS and ISRO’s Human Space Flight Centre have signed a memorandum of understanding to collaborate on space medicine, setting the stage for systematic research on how the human body behaves in space and how those insights can be applied to improve healthcare on Earth. The agreement aligns with India’s expanding human spaceflight ambitions and is expected to strengthen both biomedical research and astronaut health capabilities.

The collaboration creates a framework for both ground-based and space-based research across a wide spectrum of disciplines, including human physiology, cardiovascular and autonomic regulation, musculoskeletal health in microgravity, microbiome and immunology, genomics and biomarkers, and behavioural health. These areas are central to understanding how prolonged stays in space affect organs, systems and overall human performance, and to developing countermeasures that can be translated to clinical care back on Earth.

Explaining the medical significance, Prof. K.K. Deepak, former head of physiology at AIIMS, said research on bodily changes in microgravity can mirror and illuminate disease and ageing processes seen in hospitals. “In microgravity, astronauts experience muscle loss, bone weakening and fluid shifts in the body — changes that resemble accelerated ageing. Studying these processes helps scientists understand how ageing affects muscles, bones and circulation in people on Earth,” he said. Technologies developed to counter these effects, such as devices that improve blood flow in the legs, could support treatment of circulation problems and help maintain muscle strength in patients, he added.

AIIMS director Prof M Srinivas described the pact as a catalyst for a new phase of medical innovation that goes beyond traditional hospital-based research. “This MoU will give us the escape velocity to venture into space medicine. Research between AIIMS and ISRO will benefit patients, the nation and ultimately humankind,” he said. Officials indicated that AIIMS’ role will span protocol development, physiological monitoring, countermeasure testing and analysis of biological samples, working in tandem with ISRO’s human spaceflight teams.

The memorandum of understanding was signed by AIIMS director M. Srinivas and Dinesh Kumar Singh, director of ISRO’s Human Space Flight Centre, in the presence of ISRO chairman and secretary, Department of Space, V. Narayanan, along with senior faculty and students from the institute. The event also featured an overview of AIIMS’ ongoing work in space medicine research, presented by Prof Deepak, underscoring that the institute has already begun laying the scientific groundwork for such collaboration.

Addressing the gathering, Narayanan traced the arc of India’s space programme, from its early days when rockets and equipment were transported on bicycles and bullock carts to its current status as a global player in space technology. He said partnerships with institutions such as AIIMS will be crucial to building robust human spaceflight capabilities, adding a strong biomedical pillar to India’s launch, spacecraft and mission operations strengths.

Officials said the partnership marks a significant step in consolidating India’s capabilities in human spaceflight and biomedical research as the country advances its space ambitions. By tying clinical expertise at AIIMS with ISRO’s mission infrastructure, the collaboration is expected to generate data and technologies that support astronaut safety, deepen understanding of human biology under extreme conditions and open pathways for new diagnostics and therapies that can be applied far beyond the space programme.

Read Next

‘One Nation, One Emergency Helpline’ Proposal for Stroke Care Gains Momentum at FICCI Meet
News
April 16, 2026

‘One Nation, One Emergency Helpline’ Proposal for Stroke Care Gains Momentum at FICCI Meet

India’s stroke crisis demands urgent action, and the Indian Stroke Association (ISA) is leading the charge with a bold proposal for a unified national helpline. The ISA presented a comprehensive plan to strengthen stroke care delivery at a FICCI-hosted meeting attended by policymakers, healthcare leaders, and clinical experts. The plenary session, “Strengthening Stroke Care Delivery,” […]
Article by: IMT News Desk
Ivory raises fresh capital to strengthen deep tech offerings
News
April 16, 2026

Ivory raises fresh capital to strengthen deep tech offerings

Ivory, a brain health platform focused on early cognitive screening, has raised $1M in fresh funding, onboarding new investors to deepen its product, clinical and IP capabilities. The round saw participation from Draper Associates, a global venture capital firm with a strong focus on biotech and healthtech, along with SAGE Venture Fund, an AIF fund launched […]
Article by: IMT News Desk
Rubicon Research Enters Indian CNS Formulations Market with Strategic Acquisition
News
April 16, 2026

Rubicon Research Enters Indian CNS Formulations Market with Strategic Acquisition

Rubicon Research Limited today announced the acquisition of an 85% equity ownership in Arinna Lifesciences Limited from its current shareholders. With a portfolio of over 60 brands in chronic therapies, Arinna is one of the few domestic formulation companies principally focused on drugs treating conditions of the central nervous system (“CNS”) with more than 4,000 […]
Article by: IMT News Desk
MSN Laboratories Launches ‘SEMABEST, the First Integrated Made-in-India Semaglutide
News
April 16, 2026

MSN Laboratories Launches ‘SEMABEST, the First Integrated Made-in-India Semaglutide

MSN Laboratories has launched SEMABEST, its semaglutide brand, in the Indian market following approval from the Central Drugs Standard Control Organisation (CDSCO). SEMABEST is priced at nearly 50% lower than the innovator drug, significantly improving affordability and patient access. The therapy is available as a pre-filled pen for subcutaneous administration. In this evolving landscape, SEMABEST […]
Article by: IMT News Desk